Wockhardt Limited (NSE:WOCKPHARMA)
1,349.30
+0.70 (0.05%)
Jan 28, 2026, 1:40 PM IST
Wockhardt Revenue
Wockhardt had revenue of 7.82B INR in the quarter ending September 30, 2025, a decrease of -3.34%. This brings the company's revenue in the last twelve months to 30.07B, up 0.87% year-over-year. In the fiscal year ending March 31, 2025, Wockhardt had annual revenue of 30.35B with 7.24% growth.
Revenue (ttm)
30.07B
Revenue Growth
+0.87%
P/S Ratio
7.29
Revenue / Employee
13.10M
Employees
2,296
Market Cap
219.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 30.35B | 2.05B | 7.24% |
| Mar 31, 2024 | 28.30B | 1.73B | 6.51% |
| Mar 31, 2023 | 26.57B | -5.73B | -17.74% |
| Mar 31, 2022 | 32.30B | 5.22B | 19.28% |
| Mar 31, 2021 | 27.08B | -1.36B | -4.78% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ipca Laboratories | 93.59B |
| Piramal Pharma | 89.36B |
| Emcure Pharmaceuticals | 84.49B |
| Alembic Pharmaceuticals | 70.83B |
| Laurus Labs | 67.22B |
| Gland Pharma | 58.01B |
| Ajanta Pharma | 49.73B |
| NATCO Pharma | 43.90B |
Wockhardt News
- 1 day ago - Wockhardt shares in focus after Phase 3 success of novel antibiotic Foviscu - Business Upturn
- 21 days ago - Wockhardt files Marketing Authorisation Application to EMA for antibiotic WCK 5222 - Business Upturn
- 4 weeks ago - Wockhardt shares in spotlight after EMA grants accelerated assessment to WCK 5222 - Business Upturn
- 2 months ago - Wockhardt shares rally sharply over 9% as US FDA accepts NDA for breakthrough antibiotic Zaynich - Business Upturn
- 2 months ago - Wockhardt secures historic US FDA acceptance for antibiotic Zaynich - Business Upturn
- 4 months ago - Wockhardt submits NDA to US FDA for novel antibacterial Zidebactam-Cefepime - Business Upturn
- 4 months ago - Wockhardt shares fall over 5% after Trump’s pharma tariff announcement - Business Upturn
- 5 months ago - Shukra Pharmaceuticals secures Pan-India distribution rights from Wockhardt - Business Upturn